Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Thailand is examining the feasibility of adopting new global guidelines on long-acting HIV prevention, following the World Health Organisation's (WHO) launch of its latest recommendations for ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.